NanoLogix Unveils Advanced DNA Extraction System for Molecular Diagnostics Market

    SHARON, Pa., May 25 /PRNewswire-FirstCall/ -- NanoLogix, Inc.,
 (Pink Sheets:   NNLX), a Nano-biotechnology company engaged in the research,
 development and commercialization of technologies for the production of
 bacteria and disease testing kits, alternative sources of fuel, and
 remediation of toxic materials, announced today that its DNA extraction system
 and protocol is both easier -- due to less steps, and quicker -- taking
 significantly less time than standard spin column extraction methods according
 to Paul Hyman, Ph.D. at Ohio State University.
     According to Jain PharmaBiotech, in the year 2005, the global market for
 molecular diagnostics will be worth $6.5 billion, representing approximately
 3.3% of the total diagnostics market and approximately 14% of the in vitro
 diagnostic market. The molecular diagnostics market will expand to $12 billion
 by 2010 and $35 billion by 2015. A major portion of it can be attributed to
 advances in genomics and proteomics. Biochip and nanobiotechnology are
 expected to make a significant contribution to the growth of molecular
 diagnostics.
     Paul Hyman, Ph.D. stated, "The NanoLogix buffer allowed the DNA extraction
 from different strains of mycobacteria, requiring a single buffer, one
 incubation and one post-lysis centrifugation compared to other products, like
 Qiagen's QIAamp procedure, which utilizes six buffers, three incubations and
 four post-lysis centrifugations."
     The NanoLogix MycoExtract Buffer provides for the extracted DNA to be
 precipitated and resuspended in water.  Further, the extracted DNA in the
 NanoLogix MycoExtract Buffer can be used directly for molecular procedures
 such as PCR, which also results in further time-savings. According to a
 BioInformatics study, nearly 84% of scientists surveyed use PCR when
 extracting DNA.  Finally, because lysis in the NanoLogix MycoExtract Buffer is
 accomplished by a thirty (30) minute incubation period at 95 degrees
 centigrade, any unlysed cells are killed and the final steps of the procedure,
 as well as any down stream procedures can be done outside of a biocontainment
 hood.
     Initial applications of molecular diagnostics were mostly for infections,
 but are now increasing in the areas of genetic disorders, preimplantation
 screening and cancer. Genetic screening tests, despite some restrictions are a
 promising area for future expansion of in vitro diagnostic market. Molecular
 diagnostics is being combined with therapeutics and forms an important
 component of integrated healthcare. Molecular diagnostic technologies are also
 involved in development of personalized medicine based on pharmacogenetics and
 pharmacogenomics. Currently, there has been a considerable interest in
 developing rapid diagnostic methods for biowarfare agents such as anthrax.
     Clinical application of molecular technologies to elucidate, diagnose and
 monitor human disease has yielded over 600 diagnostic systems.  PCR has
 revolutionized molecular diagnostics and is a method of nucleic acid analysis
 for producing large amounts of a specific DNA fragment.  It can selectively
 amplify a single molecule of DNA several millionfold in a few hours.  Use of
 this technology enables the detection and analysis of specific gene sequences
 in a patient's sample without cloning.  Analyses can be performed on even a
 few cells from body fluids or even a drop of blood.  Thus, PCR eliminates the
 need to prepare large amounts of DNA from tissue samples.
     According to a Frost and Sullivan report, "The development of the
 molecular diagnostics market, coupled with a growing number of sequencing and
 functional genomic initiatives have contributed to substantial expansion of
 the marketplace."  Techniques such as cloning and peak cell rate amplification
 have moved out of the confines of genetics laboratories and have started being
 used as common research tools.
     Manufacturers have started to introduce microarrays that can analyze
 sequence variations in genes involved in drug metabolism to determine the best
 treatment regime. Moreover, diagnostic techniques of proven utility in disease
 management such as genotyping and viral load monitoring have begun to be
 applied in nucleic acid isolation and purification products. These emerging
 technologies and expanded applications of existing technologies are expected
 to enlarge the user base for nucleic acid isolation processes.  NanoLogix is
 expected to benefit from this trend.
 
     About NanoLogix, Inc.
     NanoLogix, Inc., http://www.infectech.com , is a technology application
 innovator of biogas products and services designed to assist in worldwide
 energy independence and reduce pollution from renewable, environmentally-
 friendly energy sources. NanoLogix is also engaged in the research and
 development of diagnostic test kits designed to be used for the rapid
 identification of infectious human diseases. The Company's patents span the
 identification and antibiotic sensitivity testing of 34 disease-producing
 bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
 (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes
 of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
 Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis
 in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for
 inducing a genetically based induction of "cell suicide" in cells.
     NanoLogix's patents have nanotechnology applications in medical
 drugs/devices, biodefense sensors, hydrogen production, cancer treatment and
 bioremediation.  Nanotechnology applications include Biochips embedded in
 small transportable devices for rapid bacteria identification of disease
 causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for
 rapid environmental microbial monitoring with biodefense implications. Its
 hydrogen bioreactor research is designed to assist in worldwide energy
 independence and reduce pollution using renewable, environmentally-friendly
 energy sources.  NanoLogix's FDA registered diagnostic test kits are designed
 to be used for the rapid identification of infectious human diseases and
 identify 34 disease-producing bacteria, including Tuberculosis (TB),
 Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These
 bacteria are cited as prominent causes of morbidity and mortality in patients
 with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing
 surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of
 apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a
 method for inducing a genetically based induction of "cell suicide" in cells.
 It therefore serves as the foundation for cancer therapy. NanoLogix's other
 patents include technology designed for use in the bioremediation of
 contaminated soil and water.
 
     This press release contains statements, which may constitute "forward-
 looking statements" within the meaning of the Securities Act of 1933 and the
 Securities Exchange Act of 1934, as amended by the Private Securities
 Litigation Reform Act of 1995. Those statements include statements regarding
 the intent, belief or current expectations of NanoLogix, Inc., and members of
 its management as well as the assumptions on which such statements are based.
 Prospective investors are cautioned that any such forward-looking statements
 are not guarantees of future performance and involve risks and uncertainties,
 and that actual results may differ materially from those contemplated by such
 forward-looking statements. Important factors currently known to management
 that could cause actual results to differ materially from those in forward-
 statements include fluctuation of operating results, the ability to compete
 successfully and the ability to complete before-mentioned transactions. The
 company undertakes no obligation to update or revise forward-looking
 statements to reflect changed assumptions, the occurrence of unanticipated
 events or changes to future operating results.
 
 

SOURCE NanoLogix, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.